

Global Kaposi Sarcoma Market Size study, by Type (Epidemic, Endemic, Classic, Latrogenic), by Diagnostic, by Treatment, by End-use and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G100F1D65EA7EN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,750.00 (Single User License)

ID: G100F1D65EA7EN

Abstracts

The Global Kaposi Sarcoma Market is valued at approximately USD 0.11 billion in 2023 and is anticipated to grow with a moderate yet persistent CAGR of 2.89% over the forecast period 2024-2032. Kaposi Sarcoma (KS) is a rare, multifocal angioproliferative neoplasm associated predominantly with human herpesvirus 8 (HHV-8) infection. Manifesting primarily in immunocompromised individuals—most notably those with HIV/AIDS—Kaposi Sarcoma remains a clinical challenge due to its diverse morphological patterns, aggressive progression in some cases, and underlying immunological implications. As awareness surrounding rare cancers strengthens and diagnostic capabilities advance, the global market is gradually being reshaped by better detection, targeted therapies, and broader access to healthcare services, particularly in low-income and developing regions where HIV prevalence remains high.

Several key factors have contributed to the market's forward momentum. The growing global incidence of HIV, particularly in Sub-Saharan Africa and parts of Southeast Asia, continues to elevate the burden of epidemic Kaposi Sarcoma. In parallel, advancements in molecular diagnostics, biopsy imaging techniques, and the increasing availability of antiretroviral therapies (ART) have enabled earlier diagnosis and more personalized treatment approaches. Multimodal therapy involving chemotherapy, immune modulation, and targeted biologics are becoming increasingly integrated into treatment plans. However, the rarity of the disease, lack of awareness in non-endemic regions, high costs of advanced diagnostics, and limited pharmaceutical innovation act as significant roadblocks to accelerated market expansion.

Pharmaceutical companies and research institutions are gradually intensifying their focus on orphan and rare cancers, backed by regulatory incentives such as orphan drug designations, market exclusivity extensions, and research grants. This trend is fueling the development of new immunomodulatory agents, anti-angiogenesis drugs, and novel combination regimens tailored specifically for Kaposi Sarcoma. Additionally, collaborative initiatives among global health organizations and governments have been working to integrate cancer care into existing HIV/AIDS treatment infrastructure—especially in regions where access to oncological services is scarce. While first-line treatments still rely heavily on existing chemotherapeutic agents like liposomal doxorubicin and paclitaxel, newer biologicals are being evaluated in clinical trials.

Regionally, North America currently dominates the Kaposi Sarcoma Market due to its robust healthcare system, extensive R&D funding, and high awareness levels among clinicians. The region benefits from well-established HIV care programs and timely screening protocols that facilitate early diagnosis and intervention. Europe follows closely with similar advantages and increasing initiatives for rare disease funding and research. Meanwhile, the Asia Pacific region is projected to experience the fastest growth, driven by expanding healthcare access, rising incidence rates in immunocompromised populations, and government-backed oncology campaigns. Latin America and the Middle East & Africa exhibit substantial untapped potential but continue to grapple with infrastructure limitations, inconsistent disease reporting, and financial constraints in cancer treatment.

Major market player included in this report are:

Gilead Sciences, Inc.

Pfizer Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Bristol-Myers Squibb Company

Novartis AG

Merck & Co., Inc.

Johnson & Johnson Services, Inc.

Teva Pharmaceutical Industries Ltd.

Sanofi S.A.

AbbVie Inc.

Amgen Inc.

Viiv Healthcare

Cipla Ltd.

Hikma Pharmaceuticals PLC

The detailed segments and sub-segment of the market are explained below:

By Type

Epidemic

Endemic

Classic

Latrogenic

By Diagnostic

Biopsy

Imaging

Immunohistochemistry

Others

By Treatment

Chemotherapy

Antiretroviral Therapy

Immunotherapy

Others

By End-use

Hospitals

Specialty Clinics

Academic & Research Institutes

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Middle East & Africa

Saudi Arabia

South Africa

RoMEA

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL KAPOSI SARCOMA MARKET EXECUTIVE SUMMARY

- 1.1. Global Kaposi Sarcoma Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Type
 - 1.3.2. By Diagnostic
 - 1.3.3. By Treatment
 - 1.3.4. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL KAPOSI SARCOMA MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL KAPOSI SARCOMA MARKET DYNAMICS

Global Kaposi Sarcoma Market Size study, by Type (Epidemic, Endemic, Classic, Latrogenic), by Diagnostic, by T...

3.1. Market Drivers

- 3.1.1. Rising HIV/AIDS Prevalence in Endemic Regions
- 3.1.2. Advancements in Molecular Diagnostics and ART
- 3.1.3. Regulatory Incentives for Orphan and Rare Disease Therapies

3.2. Market Challenges

- 3.2.1. Disease Rarity and Low Awareness Outside Endemic Areas
- 3.2.2. High Cost of Advanced Diagnostics and Targeted Therapies
- 3.2.3. Limited Pharmaceutical Innovation in KS-Specific Agents

3.3. Market Opportunities

- 3.3.1. Orphan Drug Designations and Market Exclusivity Benefits
- 3.3.2. Integration of KS Care with HIV/AIDS Treatment Infrastructure
- 3.3.3. Emerging Biologic and Immunotherapy Pipeline

CHAPTER 4. GLOBAL KAPOSI SARCOMA MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL KAPOSI SARCOMA MARKET SIZE & FORECASTS BY TYPE 2022-2032

5.1. Segment Dashboard

5.2. Global Kaposi Sarcoma Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million)

- 5.2.1. Epidemic
- 5.2.2. Endemic
- 5.2.3. Classic
- 5.2.4. Latrogenic

CHAPTER 6. GLOBAL KAPOSI SARCOMA MARKET SIZE & FORECASTS BY DIAGNOSTIC 2022-2032

6.1. Segment Dashboard

6.2. Global Kaposi Sarcoma Market: Diagnostic Revenue Trend Analysis, 2022 & 2032 (USD Million)

- 6.2.1. Biopsy
- 6.2.2. Imaging
- 6.2.3. Immunohistochemistry
- 6.2.4. Others

CHAPTER 7. GLOBAL KAPOSI SARCOMA MARKET SIZE & FORECASTS BY TREATMENT & END-USE 2022-2032

7.1. By Treatment

- 7.1.1. Chemotherapy
- 7.1.2. Antiretroviral Therapy
- 7.1.3. Immunotherapy
- 7.1.4. Others

7.2. By End-use

- 7.2.1. Hospitals
- 7.2.2. Specialty Clinics
- 7.2.3. Academic & Research Institutes
- 7.2.4. Others

CHAPTER 8. GLOBAL KAPOSI SARCOMA MARKET SIZE & FORECASTS BY REGION 2022-2032

8.1. North America KS Market

- 8.1.1. U.S. KS Market

- 8.1.1.1. Type breakdown size & forecasts, 2022-2032
- 8.1.1.2. Diagnostic breakdown size & forecasts, 2022-2032
- 8.1.2. Canada KS Market
- 8.2. Europe KS Market
 - 8.2.1. U.K. KS Market
 - 8.2.2. Germany KS Market
 - 8.2.3. France KS Market
 - 8.2.4. Spain KS Market
 - 8.2.5. Italy KS Market
 - 8.2.6. Rest of Europe KS Market
- 8.3. Asia Pacific KS Market
 - 8.3.1. China KS Market
 - 8.3.2. India KS Market
 - 8.3.3. Japan KS Market
 - 8.3.4. Australia KS Market
 - 8.3.5. South Korea KS Market
 - 8.3.6. Rest of Asia Pacific KS Market
- 8.4. Latin America KS Market
 - 8.4.1. Brazil KS Market
 - 8.4.2. Mexico KS Market
 - 8.4.3. Rest of Latin America KS Market
- 8.5. Middle East & Africa KS Market
 - 8.5.1. Saudi Arabia KS Market
 - 8.5.2. South Africa KS Market
 - 8.5.3. Rest of Middle East & Africa KS Market

CHAPTER 9. COMPETITIVE INTELLIGENCE

- 9.1. Key Company SWOT Analysis
 - 9.1.1. Gilead Sciences, Inc.
 - 9.1.2. Pfizer Inc.
 - 9.1.3. Eli Lilly and Company
- 9.2. Top Market Strategies
- 9.3. Company Profiles
 - 9.3.1. Gilead Sciences, Inc.
 - 9.3.1.1. Key Information
 - 9.3.1.2. Overview
 - 9.3.1.3. Financial (Subject to Data Availability)
 - 9.3.1.4. Product Summary

- 9.3.1.5. Market Strategies
- 9.3.2. Pfizer Inc.
- 9.3.3. Eli Lilly and Company
- 9.3.4. F. Hoffmann-La Roche Ltd
- 9.3.5. Bristol-Myers Squibb Company
- 9.3.6. Novartis AG
- 9.3.7. Merck & Co., Inc.
- 9.3.8. Johnson & Johnson Services, Inc.
- 9.3.9. Teva Pharmaceutical Industries Ltd.
- 9.3.10. Sanofi S.A.
- 9.3.11. AbbVie Inc.
- 9.3.12. Amgen Inc.
- 9.3.13. ViiV Healthcare
- 9.3.14. Cipla Ltd.
- 9.3.15. Hikma Pharmaceuticals PLC

CHAPTER 10. RESEARCH PROCESS

- 10.1. Research Process
 - 10.1.1. Data Mining
 - 10.1.2. Analysis
 - 10.1.3. Market Estimation
 - 10.1.4. Validation
 - 10.1.5. Publishing
- 10.2. Research Attributes

I would like to order

Product name: Global Kaposi Sarcoma Market Size study, by Type (Epidemic, Endemic, Classic, Latrogenic), by Diagnostic, by Treatment, by End-use and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G100F1D65EA7EN.html>

Price: US\$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G100F1D65EA7EN.html>